{"id":"abbv-932","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a T-cell engaging bispecific antibody, ABBV-932 bridges cytotoxic T lymphocytes to tumor cells by binding CD3 on T cells and a tumor antigen on cancer cells, thereby activating and redirecting T cells to recognize and eliminate malignant cells. This mechanism leverages the body's own immune system to target cancer more specifically than conventional approaches.","oneSentence":"ABBV-932 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells to kill cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:18.380Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indications under investigation in phase 2)"}]},"trialDetails":[{"nctId":"NCT07220460","phase":"PHASE2","title":"Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-09-30","conditions":"Bipolar I or II Disorder","enrollment":200},{"nctId":"NCT06849791","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2025-02-26","conditions":"Healthy Volunteer","enrollment":9},{"nctId":"NCT06846320","phase":"PHASE2","title":"Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-29","conditions":"Generalized Anxiety Disorder (GAD)","enrollment":315},{"nctId":"NCT06605599","phase":"PHASE2","title":"Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-10-15","conditions":"Bipolar I Disorder, Bipolar II Disorder","enrollment":161},{"nctId":"NCT07024797","phase":"PHASE1","title":"Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2025-08-21","conditions":"Healthy Volunteer","enrollment":20},{"nctId":"NCT07071532","phase":"PHASE1","title":"A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Healthy Adult Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2025-07-15","conditions":"Healthy Volunteer","enrollment":20},{"nctId":"NCT06953934","phase":"PHASE1","title":"A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2025-10-14","conditions":"Healthy Volunteer","enrollment":8},{"nctId":"NCT06300580","phase":"PHASE1","title":"Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-08-21","conditions":"Healthy Volunteers","enrollment":11},{"nctId":"NCT06024239","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-08-31","conditions":"Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)","enrollment":72},{"nctId":"NCT05738850","phase":"PHASE1","title":"Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-02-15","conditions":"Generalized Anxiety Disorder (GAD), Healthy Participants","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABBV-932","genericName":"ABBV-932","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABBV-932 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells to kill cancer cells. Used for Solid tumors (specific indications under investigation in phase 2).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}